Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company MABLife S.A.S
DescriptionChimeric mAb targeting CD5
Molecular Target CD5
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat or prevent lymphoproliferative diseases
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today